Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

The Market Online’s Weekly Cannabis Report – April 5, 2024

Jonathon Brown Jonathon Brown, The Market Online
0 Comments| April 5, 2024

{{labelSign}}  Favorites
{{errorMessage}}

Tilray Brands has revealed its 420-themed product lineup for 2024. The launches will be complemented by a series of educational 420 budtender events across Canada in partnership with more than 1,000 cannabis retailers.

Click to enlarge
(Source: Roman)

Click here for the full story.

Weekly Update – Top Cannabis News Stories

1 | Top Story: This CBD company submitted its third product application for approval to COFEPRIS, the Federal Commission for Protection Against Sanitary Risk, in Mexico

2 | Licensed cannabis producer’s popular brand surpasses $200 million in yearly retail sales

3 | Biotech firm and licensed cannabis processor applauds Health Canada’s recommendation to expand access to medical cannabis through pharmacies

Click to enlarge

Top Cannabis Stocks March 29 to April 4, 2024

1. T.WEED | 32,162 views | Canopy Growth Corp.
2. T.TLRY | 25,573 views | Tilray Brands Inc.
3.T.LABS | 14,218 views | Medipharm Labs Corp.
4. T.CURA | 4,861 views | Curaleaf Holdings Inc.
5. T.DN | 2,431 views | Delta 9 Cannabis Inc.
6.T.ACB| 2,310 views | Aurora Cannabis Inc.


The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.



{{labelSign}}  Favorites
{{errorMessage}}